Patrick Daly

DocwireNews

In the IKEMA trial, researchers compared carfilzomib and dexamethasone plus isatuximab against carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma (MM). Updated data were published in&nbsp;Clinical Lymphoma, Myeloma &amp; Leukemia, wherein researchers showed that treatment with isatuximab yielded with clinically meaningful improvements in duration of response (DOR) compared to treatment without isatuximab.The phase 3, open-label IKEMA trial enrolled patients with relapsed MM after 1 to 3 prior lines of treatment. Researchers administered intravenous isatuximab 10 mg/kg QW for 4 weeks, followed by Q2W to the treatment arm. Both the treatment and control arm received intravenous carfilzomib and oral/intravenous dexamethasone. The primary end point of the study was progression-free survival (PFS), while additional endpoints included complete response (CR) and minimal residual disease (MRD) measures.<h3>Isatuximab Appears Effective in Relapsed MM</h3>According to the investigators, over a median follow-up period of 44 months by the January 2022 data cutoff, patients in the isatuximab with carfilzomib and dexamethasone group achieved deeper responses compared to patients in the carfilzomib and dexamethasone group, with &ge;CR rates of 44.1% versus 28.5%, respectively (odds ratio [OR], 2.09; 95% CI, 1.26-3.48; P=.0021).Likewise, MRD- occurred in 33.5% of isatuximab, carfilzomib and dexamethasone patients versus 15.4% of carfilzomib and dexamethasone patients (OR, 2.78; 95% CI, 1.55-4.99;&nbsp;P=.0002).&nbsp;Overall, 26.3% of the isatuximab group achieved both &ge;CR and MRD- compared with 12.2% in the control group (OR, 2.57; 95% CI, 2.35-4.88;&nbsp;P=.0015). Isatuximab also appeared to improve outcomes for MRD+ patients.In closing, the authors highlighted that the &ldquo;impressive &ge;CR and &ge;CR+MRD- (10-5) rates in Isa-Kd versus Kd are the highest reported for proteasome inhibitor-based regimens in relapsed MM. Achieving MRD- led to better outcomes in both arms; Isa-Kd patients had &gt;2-fold higher likelihood of achieving MRD-.&rdquo;View More <a href="https://www.docwirenews.com/multiple-myeloma-knowledge-hub/">Multiple Myeloma Research and Expert Interviews</a>

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Carfilzomib and Dexamethasone With or Without Isatuximab in MM

Oncology

In the IKEMA trial, researchers compared carfilzomib and dexamethasone plus isatuximab against carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe